Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. - Wikidata - awgldk - TriplyDB

Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.

Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.

http://www.wikidata.org/entity/Q34642403

about

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms Clinical potential of pacritinib in the treatment of myelofibrosis New molecular targets in mantle cell lymphoma Customized targeted therapy in Hodgkin lymphoma: hype or hope?Protein kinase inhibitors against malignant lymphoma Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.The development, safety and efficacy of pacritinib for the treatment of myelofibrosis.Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies Genetic methylation and lymphoid malignancies: biomarkers of tumor progression and targeted therapy.Oncogene withdrawal engages the immune system to induce sustained cancer regression.An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.Molecular targeted approaches in mantle cell lymphoma.Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma Molecular pathogenesis of mantle cell lymphoma.Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer Beyond chemotherapy: new agents for targeted treatment of lymphoma Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.Targeting oncogenic and epigenetic survival pathways in lymphoma.New strategies in Hodgkin lymphoma: better risk profiling and novel treatments.Leveraging cancer genome information in hematologic malignancies.Mutations and chromosomal rearrangements of JAK2: not only a myeloid issue.Signaling pathways in lymphoma: pathogenesis and therapeutic targets.Diffuse large B-cell lymphoma-treatment approaches in the molecular era.Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application.Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma.STAT3 inhibitors: finding a home in lymphoma and leukemia.

P2860

Q26770716-69AACBE4-5FE6-41B4-B93B-908FAB4A7CBB Q26782270-1FAFBE31-7058-4F23-AE02-0E8CC6D1A781 Q26795594-3F2D352B-5BAB-47D1-A9D6-A6475D8EE591 Q26796450-3196D2FC-613D-4A13-B908-75A6711A26B1 Q26821766-19F9A902-6002-4C58-89AC-8835135B9D7A Q27002554-8F90B240-F281-4B31-80CB-C5A90B62AD8E Q27024212-C779EB70-A8DF-4E1F-B29E-B3F6950A31B6 Q27027729-A3502654-62D0-46BF-8DEF-FCE30810F769 Q27304386-2810B2CA-A437-42BA-A558-7FE32247FB2B Q33421108-ECF564DC-766F-43FD-84A8-55C82E1B42F4 Q33435178-3B7C3A83-FE06-400A-A44E-EB7F963B577D Q33622342-5F148F7C-38FD-4F01-A301-F73219982C91 Q33886243-307C80E1-B9E1-494E-ADE1-9487E6B8C064 Q33886267-DA23902E-46E7-4AA9-93B4-397576546068 Q33913937-731A92A9-3AFE-4579-A728-24F7D763812B Q33987633-E11257BC-1E77-4274-9E08-5F1EC4E9BA93 Q34361976-3845B681-A9B7-4571-8BAF-80F6A59825DC Q34448586-D77865FE-8096-4F30-8B70-045AE43FD247 Q34640779-A9487819-6904-4212-89E2-943AFE27BEB9 Q34648812-2105776A-E703-4180-91AB-6093BB6D294A Q35127368-9FE1DD8E-7F2B-4610-A0B9-5A1D4AD948FA Q35132241-0FF476F1-F2A4-4F60-94E7-EA712B269C84 Q35987564-45E5DD0D-091E-4660-A182-0BA024C99E7A Q36042686-0983F48C-AE58-4357-951B-3A58AE338A0D Q36290246-FBA5F15D-C0FE-4E02-88E0-DD1BA5AFF497 Q36598782-2209A256-08EC-460D-AF00-6075B659A310 Q36689024-A79933D1-C9EC-4071-A47F-3306EEB9F99A Q37820097-A5553BFF-6599-4BD7-BCE8-0908B653834C Q37872044-7CAAEF4A-06D4-449A-A0CC-FBF521E25EBB Q38077992-5EA9472C-529E-4B35-A3B5-1081CC6086A6 Q38081267-B8D06CA1-7C60-4298-B373-DF921B0689A3 Q38084734-CA34BEF5-F454-4F8B-B898-CD35BCD3ED3A Q38085250-CF562BBA-A90F-499A-A23F-BD2E25A592FC Q38099307-8DCB7ABA-61E8-478F-85B0-34AF2A41A548 Q38132817-43CCBC51-C537-470D-946A-E84BB645CF35 Q38150876-214923A6-9209-40E0-B238-B68497626A06 Q38161760-E4B125E1-47A6-42E7-B6C5-026BEB87BA18 Q38164139-F404CC3F-8C76-49B7-A4D9-0132CE08F5F6 Q38179500-7492E171-9099-4A83-981F-61E690ED3C3F Q38202556-F978F2F9-2E44-4581-9568-16372AEC7BD5

P2860

Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.

http://www.wikidata.org/entity/Q34642403

description

2012 nî lūn-bûn

@nan

2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Phase I study of a novel oral ...... in multiple lymphoma subtypes.

@ast

Phase I study of a novel oral ...... in multiple lymphoma subtypes.

@en

Phase I study of a novel oral ...... in multiple lymphoma subtypes.

@nl

type

label

Phase I study of a novel oral ...... in multiple lymphoma subtypes.

@ast

Phase I study of a novel oral ...... in multiple lymphoma subtypes.

@en

Phase I study of a novel oral ...... in multiple lymphoma subtypes.

@nl

prefLabel

Phase I study of a novel oral ...... in multiple lymphoma subtypes.

@ast

Phase I study of a novel oral ...... in multiple lymphoma subtypes.

@en

Phase I study of a novel oral ...... in multiple lymphoma subtypes.

@nl

P1433

Q34642403-E5EA3250-E431-4F59-A09C-06596F255FD2

P1476

Q34642403-75825BDB-BB14-4AEB-941C-8BED42A24FFF

P2093

Q34642403-0ECBB60D-59EC-4082-A09B-F1B94E21989D

Q34642403-1C3C5027-D398-4DBC-9727-B05E3ADF138E

Q34642403-30C97111-62BC-4B13-9895-BD3DCEBFB86C

Q34642403-3D379B85-4027-4F07-B643-F296750849DC

Q34642403-574DB430-BE28-44AE-8309-B61F54DB3D42

Q34642403-6C594C64-4BD2-40C7-AB2E-AAA1CF776C2A

Q34642403-6E2145E8-1A3A-422E-93A0-74430935F6EE

Q34642403-9E292ADE-A9EB-4133-A862-4AE4D04F6C30

Q34642403-A22D44F6-F9FD-4642-82A1-B52273ED2063

Q34642403-C9C8D076-FE35-4D48-9FF5-A5D2FB719B7D

P2860

Q34642403-03357972-EABC-46ED-83B2-3C0E228441E3

Q34642403-0EC28E92-834A-46DA-968B-8D30058B8522

Q34642403-17FFD695-F0E1-41E2-B313-8E83813931A4

Q34642403-2C3E57C0-3E51-4E8B-B4E0-F1E0DAA35699

Q34642403-32195F68-C43E-4F78-9115-1FB0EB409024

Q34642403-332C920A-5788-4AE8-8D76-C7973FCE1D78

Q34642403-34A2861A-27E3-44B5-B032-6F4A9AD1550E

Q34642403-3C94D9DB-2BD0-41AC-8E31-C4E7873C4C15

Q34642403-4C73DCE3-F115-42EE-BCFF-11FC2348297C

Q34642403-51D07372-CFA3-4EBE-B219-0C121A068BDC

P304

Q34642403-DF9E694F-9F59-4A8C-82C6-A6D67C29A2C2

P31

Q34642403-04C58E1D-720F-43AC-B460-2429BCE589A4

P356

Q34642403-57F3A111-AF9D-4B7E-910E-EA0A5094AB08

P407

Q34642403-3F7226D8-C826-46EE-A662-EBE43C8ECD2A

P433

Q34642403-25E3B04F-4BD2-4096-9505-EFCBDE065EFB

P478

Q34642403-9DBBB951-9A7F-4A00-B218-1DEC02A7390F

P577

Q34642403-BC39D9EC-EB0C-43BE-91FF-D64866A06062

P698

Q34642403-0A362057-C11B-4883-8A3D-2B035FF57981

P921

Q34642403-CAB0935B-F5CF-4A5A-887A-ADD20C0986D2

P932

Q34642403-459C4ED0-0084-4300-BA3D-D33D6E1B21D4

P356

JCO.2012.42.5223

P1433

Journal of Clinical Oncology

P1476

Phase I study of a novel oral ...... in multiple lymphoma subtypes.

@en

P2093

Amanda Copeland

http://www.w3.org/2001/XMLSchema#string

Anas Younes

http://www.w3.org/2001/XMLSchema#string

Frederick Hagemeister

http://www.w3.org/2001/XMLSchema#string

Jatin Shah

http://www.w3.org/2001/XMLSchema#string

Jeanette Wood

http://www.w3.org/2001/XMLSchema#string

Jorge Romaguera

http://www.w3.org/2001/XMLSchema#string

Joy Zhu

http://www.w3.org/2001/XMLSchema#string

Kantharaj Ethirajulu

http://www.w3.org/2001/XMLSchema#string

Larry Kwak

http://www.w3.org/2001/XMLSchema#string

Michelle Fanale

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhi

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies.

Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma.

Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study.

Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma.

Targeting the interleukin-6/Jak/stat pathway in human malignancies

JAK/STAT signal transduction: regulators and implication in hematological malignancies.

P304

4161-4167

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2012.42.5223

http://www.w3.org/2001/XMLSchema#string

P407

P433

33

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22965964

http://www.w3.org/2001/XMLSchema#string

P921

P932

5950499

http://www.w3.org/2001/XMLSchema#string